Stocktoria
Mineralys Therapeutics, Inc. MLYS
Mineralys Therapeutics, Inc. (MLYS) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-04-27 | TD Cowen | Buy (init) |
| 2026-03-13 | B of A Securities | Buy (main) |
| 2025-12-19 | Stifel | Buy (main) |
| 2025-11-12 | HC Wainwright & Co. | Buy (main) |
| 2025-11-11 | Wells Fargo | Overweight (main) |
| 2025-10-30 | HC Wainwright & Co. | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | 3/9 | — | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
FAQ
Is MLYS financially healthy?
Mineralys Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does MLYS pay a dividend?
No, Mineralys Therapeutics, Inc. does not currently pay a dividend.
How profitable is MLYS?
In FY2025, Mineralys Therapeutics, Inc. had a return on equity of -23.9%.
What is the analyst price target for MLYS?
The average Wall-Street price target for Mineralys Therapeutics, Inc. is $49.00, about 81.1% above the recent price, from 8 analysts (consensus: strong buy).
Is MLYS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Mineralys Therapeutics, Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.